Sponsored by:
Accelerating Biosimilar Development with Octet® BLI Technology
Biosimilar development is a rapidly growing field in the pharmaceutical industry. These regulated drug “reproductions” help to lower healthcare costs and increase access to vital medicines. However, the inherent complexity of producing a biologically active copy of a protein means that high similarity to the reference medicinal product is required.
This article discusses how a single analyte concentration can be used to accelerate biosimilar development when using an Octet® Bio-Layer Interferometry (BLI) Label-Free Detection Systems for biomolecular interactions analysis.
Key Takeaways
- Biosimilars offer a lower cost alternative to branded biologics
- Single analyte concentration screens can rapidly increase sample throughput against multiple targets
- Octet® BLI systems accelerate biosimilar development with real-time molecular interaction data
- Octet® BLI systems simplify sample analysis, reducing time and cost
- High-throughput screening with Octet® BLI increases development efficiency
- Octet® BLI technology streamlines drug development, benefiting healthcare and patients
